| Literature DB >> 35188325 |
Rita Nasti1, Ivan Bassanini2, Erica Elisa Ferrandi2, Federica Linguardo2, Susanna Bertuletti2, Marta Vanoni2, Sergio Riva2, Luisella Verotta1, Daniela Monti2.
Abstract
Ginger is among the most widespread and widely consumed traditional medicinal plants around the world. Its beneficial effects, which comprise e. g. anticancer and anti-inflammatory activities as well as gastrointestinal regulatory effects, are generally attributed to a family of non-volatile compounds characterized by an arylalkyl long-chained alcohol, diol, or ketone moiety. In this work, ginger active components have been successfully recovered from industrial waste biomass of fermented ginger. Moreover, their recovery has been combined with the first systematic study of the stereoselective reduction of gingerol-like compounds by isolated alcohol dehydrogenases (ADHs), obtaining the enantioenriched sec-alcohol derivatives via a sustainable biocatalytic path in up to >99 % conversions and >99 % enantiomeric/diastereomeric excesses.Entities:
Keywords: biocatalysis; challenging ketones; ginger active components; stereoselectivity; waste valorization
Mesh:
Substances:
Year: 2022 PMID: 35188325 PMCID: PMC9314113 DOI: 10.1002/cbic.202200105
Source DB: PubMed Journal: Chembiochem ISSN: 1439-4227 Impact factor: 3.461
Figure 1Structures of main ginger active components (a) and optically active diols and alcohol derivatives obtained in this study (b).
Figure 2Extraction of gingerol‐like compounds from fresh ginger (a) and ginger fermentation residues (b).
Characterization and yields of gingerol‐like compounds from fresh ginger and ginger lees.
|
Compound |
Retention time [min] |
(−)‐ESI‐MS [m/z] |
Fresh ginger [% w/w] |
Ginger lees [% w/w] |
|---|---|---|---|---|
|
|
7.15 |
293.61 |
11.4 |
5.43 |
|
|
8.49 |
321.47 |
2.69 |
0.94 |
|
|
8.75 |
275.39 |
2.39 |
1.31 |
|
|
9.76 |
349.47 |
4.50 |
1.66 |
Scheme 1General scheme of the biocatalyzed reduction of ginger active compounds (1 a–b, 3 and 4). The glucose/GDH system is used for cofactor regeneration.
Screening of alcohol dehydrogenases in the stereoselective reduction of 1 a and 4.
|
Entry |
Enzyme[a] |
Substrate | |||
|---|---|---|---|---|---|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
1 |
Ec‐ADH |
>99 |
99 ( |
– |
– |
|
2 |
Tb‐ADH |
19 |
61 ( |
– |
– |
|
3 |
HL‐ADH |
8 |
15 ( |
– |
– |
|
4 |
Ml‐ADH[c] |
– |
– |
96 |
97 ( |
|
5 |
Lk‐ADH[d] |
68 |
98 ( |
– |
– |
|
6 |
Rr‐ADH |
>95 |
>99 ( |
– |
– |
|
7 |
Lb‐ADH[c] |
>95 |
>99 ( |
– |
– |
|
8 |
Cp‐ADH |
18 |
52 ( |
– |
– |
|
9 |
Is2‐SDR[c] |
24 |
83 ( |
50 |
>95 ( |
|
10 |
evo‐1.1.010[e] |
54 |
87 ( |
>99 |
91 ( |
|
11 |
evo‐1.1.020[e] |
96 |
97 ( |
>99 |
94 ( |
|
12 |
evo‐1.1.030[e] |
>99 |
>99 ( |
12 |
>99 ( |
|
13 |
evo‐1.1.040[e] |
54 |
34 ( |
– |
– |
|
14 |
evo‐1.1.130[e] |
26 |
67 ( |
13 |
>99 ( |
|
15 |
evo‐1.1.140[e] |
<10 |
–[f] |
– |
– |
|
16 |
evo‐1.1.190[e] |
18 |
48 ( |
– |
– |
|
17 |
evo‐1.1.200[e] |
>99 |
>99 ( |
88 |
6 ( |
|
18 |
evo‐1.1.210[e] |
>99 |
51 ( |
<10 |
–[f] |
|
19 |
evo‐1.1.250[e] |
52 |
<5 ( |
90 |
>99 ( |
|
20 |
evo‐1.1.260[e] |
85 |
88 (S) |
18 |
>99 ( |
|
21 |
evo‐1.1.270[e] |
>99 |
>99 ( |
50 |
>99 ( |
|
22 |
evo‐1.1.380[e] |
36 |
28 ( |
32 |
>99 ( |
|
23 |
evo‐1.1.420[e] |
>99 |
>99 ( |
<5 |
–[f] |
|
24 |
evo‐1.1.430[e] |
56 |
60 ( |
<5 |
–[f] |
|
25 |
evo‐1.1.440[e] |
>99 |
>99 ( |
>99 |
74 ( |
|
26 |
evo‐1.1.441[e] |
>99 |
61 ( |
46 |
66 ( |
|
27 |
evo‐1.1.442[e] |
>99 |
98 ( |
<10 |
–[f] |
[a] For details about enzymes source and production see Supporting Information. [b] Conversions and enantiomeric/diastereomeric excesses (ee values/de values) determined by chiral phase HPLC analysis (Method C, see Experimental Section for details) after 72 h at 30 °C if not stated otherwise. [c] Reactions performed at 25 °C. [d] Reactions performed at 20 °C in the presence of 5 mg mL−1 purified Lk‐ADH. [e] Reactions performed according to the manufacturer (evoxx technologies GmbH, see Experimental Section for details). [f] Not determined, below detection limit.
Scheme 2Cascade synthesis of (/( from 2 by coupling of the ene reductase OYE3 with selected (R)‐ or (S)‐selective ADHs.
Screening of selected commercially available ADHs in the stereoselective reduction of 1 b and 3.
|
Entry |
Enzyme[a] |
Substrate | |||
|---|---|---|---|---|---|
|
|
|
|
| ||
|
|
|
|
| ||
|
1 |
evo‐1.1.010 |
98 |
>99 ( |
>99 |
96 ( |
|
2 |
evo‐1.1.020 |
93 |
>99 ( |
>99 |
50 ( |
|
3 |
evo‐1.1.250 |
– |
– |
>99 |
76 ( |
|
4 |
evo‐1.1.440 |
46 |
7 ( |
>99 |
26 ( |
[a] Commercially available from evoxx technologies GmbH (Monheim am Rhein, Germany). [b] Conversions and enantiomeric/diastereomeric excess values determined by chiral phase HPLC analysis after 72 h at 30 °C (Method B, see Experimental Section for details).
Scheme 3Stereoselective synthesis of (/( from 4 on a semi‐preparative scale (100 mg of 4) by using Rr‐ADH or Lb‐ADH, respectively.